C14 Study in Oncology Patients With Advanced and/or Metastatic Solid Tumors
Status:
Completed
Trial end date:
2012-02-01
Target enrollment:
Participant gender:
Summary
This is an open-label study being conducted to determine the metabolism and physiological
disposition of radiolabeled LY2603618 after a single dose in patients with advanced and/or
metastatic solid tumors.
After a minimum 7-day washout period following the carbon-14-labeled LY2603618
([^14C]LY2603618) dose, patients will be allowed to continue to receive continued access to
LY2603618 in combination with pemetrexed or gemcitabine as outpatients.